Unknown

Dataset Information

0

Recent progress in the strategic incorporation of fluorine into medicinally active compounds.


ABSTRACT: This account exemplifies our recent progress on the strategic incorporation of fluorine and organofluorine groups to (i) taxoid anticancer agents, (ii) acylhydrazone-based antifungal agents and (iii) inhibitors of matrix metalloproteinase 9 (MMP9) for medicinal chemistry and chemical biology studies. In the case study (i), a series of next-generation fluorotaxoids, bearing m-OCF3 or m-OCF2H group in the C2-benzoate moiety was designed, synthesized and examined for their potencies. A number of these fluorotaxoids possess two orders of magnitude greater potency in different drug-resistant cancer cell lines as compared to paclitaxel. One of these next-generation fluorotaxoids, SB--121205wasselected for detailed mechanistic study against highly paclitaxel-resistant human breast cancer cell line, MCF-7/PTX, which disclosed a unique mechanism of action. Recently, glucosylceramide (GlcCer) synthesis emerged as a promising target for next-generation antifungal agents, especially against cryptococcosis, candidiasis and pulmonary aspergillosis. The HTP screening of compound libraries identified several acylhydrazones as hit compounds. In the case study (ii), fluoro-acylhydrazones containing F, OCF3, OCHF2, o-F/p-OCF3, as well as o-F/p-CF3 functional groups in the ring A and ring B were designed based on these hit compounds, synthesized and examined for their potencies against C. neoformans. A number of those novel fluoro-acylhydrazones exhibited high potency and excellent killing properties. The hemopexin-like domain of matrix metalloproteinases (MMPs) is a highly promising target to circumvent the critical issue in the development of MMP inhibitors for the treatment of various cancers. In the case study (iii), a small optimization library of compounds, based on the OCHF2-containing hit compound, SB-M-001, was generated and evaluated, which identified a fluorine-containing new lead compound, SB-M-103. SB-M-103 was found to inhibit tumor cell growth, migration, and invasion by effectively disrupting the MMP-9 homodimerization.

SUBMITTER: Haranahalli K 

PROVIDER: S-EPMC6752223 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Recent progress in the strategic incorporation of fluorine into medicinally active compounds.

Haranahalli Krupanandan K   Honda Tadashi T   Ojima Iwao I  

Journal of fluorine chemistry 20181103


This account exemplifies our recent progress on the strategic incorporation of fluorine and organofluorine groups to (i) taxoid anticancer agents, (ii) acylhydrazone-based antifungal agents and (iii) inhibitors of matrix metalloproteinase 9 (MMP9) for medicinal chemistry and chemical biology studies. In the case study (i), a series of next-generation fluorotaxoids, bearing <i>m</i>-OCF<sub>3</sub> or <i>m</i>-OCF<sub>2</sub>H group in the C2-benzoate moiety was designed, synthesized and examined  ...[more]

Similar Datasets

| S-EPMC5445929 | biostudies-literature
| S-EPMC4167679 | biostudies-literature
| S-EPMC3769458 | biostudies-literature
| S-EPMC8442002 | biostudies-literature
| S-EPMC6965068 | biostudies-literature
| S-EPMC7177952 | biostudies-literature
| S-EPMC8522369 | biostudies-literature
| S-EPMC5458863 | biostudies-other
| S-EPMC8293999 | biostudies-literature
| S-EPMC2593907 | biostudies-literature